Advances in Transfusion Safety: San Francisco, CA, USA March 18-20, 1999
Girish N. Vyas, Fred Brown, University of California School of Medicine, San Francisco
Karger, Jan 1, 2000 - Medical - 244 pages
Our current understanding of the molecular mechanisms underlying host-parasite interaction in the establishment of persistent infections transmitted through blood transfusion permits us to develop strategies for their prevention. Because of rigorous screening to prevent transmission of blood-borne infections, the transfusion of blood and blood products has already achieved an unprecedented level of safety. The «window period» viraemia can be further reduced by screening donated blood with nucleic acid testing (NAT) technology now being introduced in Europe and the U.S.A. Both immunological and virological risks of transfusion can be reduced by photodecontamination and universal leukofiltration performed at the blood processing facilities. Unquestionably, progressive improvements in transfusion safety leads to an escalation in the cost of our blood supply; therefore, cost effectiveness, quality control, and regulatory issues have become topics of considerable importance in responding to our society's expectation of risk-free hemotherapy.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Immunobiology of Persistent BloodBorne Viral Infections
Risk of Hepatitis and Retroviral Infections Among Blood Donors and Introduction of Nucleic
20 other sections not shown
Advances in Transfusion agents anti-HCV antibody antigen assay Basel blood and blood blood banks Blood Center blood components blood donors blood safety blood supply blood transfusion Brown F Busch MP cellular blood products clinical trials copies per mL Creutzfeldt-Jakob disease CV-N detection Dev Biol disease estimated evaluated fractionation genome haemoglobin HBsAg HCV RNA hepatitis C virus HIV infection HTLV incidence International Inventory Hold Karger laboratory methods minipools Molecular negative oxygen p24 antigen parvovirus B19 pathogens patients PCR testing Photochemical plasma pools platelet platelet concentrates positive prevalence primers probes programme protein psoralen RBCC reactive recipients red cell risk RT-PCR samples screening sensitivity septic reactions sequence seroconversion seropositive serum specimen studies Table target tion titres Transfusion Medicine Transfusion Safety transfusion-associated transfusion-transmitted transmission vaccines viral virus inactivation viruses Vyas G eds whole blood window period